{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:29:20Z","timestamp":1780471760065,"version":"3.54.1"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To perform a comparative effectiveness feasibility study in juvenile localized scleroderma (LS), using standardized treatment regimens (consensus treatment plans; CTP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A prospective, multicenter 1-year pilot observational cohort study was performed by Childhood Arthritis and Rheumatology Research Alliance (CARRA) LS workgroup members. Patients with active, moderate to severe juvenile LS were treated with one of 3 CTP: methotrexate alone, or in combination with intravenous (30 mg\/kg\/dose for 3 mos) or oral corticosteroids (2 mg\/kg\/day tapered by 48 weeks).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Fifty patients, with demographics typical for juvenile LS, were enrolled, and 44 (88%) completed the study. Most had extracutaneous involvement. Patients improved in all 3 CTP, with &gt; 75% having a major or moderate level of improvement compared to baseline. Damage accrued in some patients. Major deviations from prescribed regimen resulted from medication intolerance (n = 6; 14%) or treatment failure (n = 11; 25%); failures occurred in all 3 CTP. Significant responses to treatment were demonstrated by LS skin scoring measures and overall physician assessments, with differences in response level identified in some patient subsets. Response differences were associated with baseline disease activity level, LS subtype, skin disease extent, and extracutaneous involvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>This study demonstrates the feasibility of conducting juvenile LS comparative effectiveness studies. The CTP were found to be safe, effective, and tolerable. Our assessments performed well. Because damage is common and may progress despite effective control of activity, we recommend initial treatment efficacy be evaluated primarily by activity measures. Potential confounders for response were identified that warrant further study.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.190311","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:49:52Z","timestamp":1571168992000},"page":"1242-1252","source":"Crossref","is-referenced-by-count":32,"title":["Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma"],"prefix":"10.3899","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-2866","authenticated-orcid":false,"given":"Suzanne C.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-143X","authenticated-orcid":false,"given":"Kathryn S.","family":"Torok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Egla","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-0848","authenticated-orcid":false,"given":"Fatma","family":"Dedeoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9901-0334","authenticated-orcid":false,"given":"Polly J.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy D.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-9310","authenticated-orcid":false,"given":"Elena","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Laxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-8002","authenticated-orcid":false,"suffix":"II","given":"Thomas","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-9310","authenticated-orcid":false,"given":"Robert C.","family":"Fuhlbrigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-390X","authenticated-orcid":false,"given":"Tracy","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2024112122583784000_47.8.1242.1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","article-title":"Immunopathogenesis of pediatric localized scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"2024112122583784000_47.8.1242.2","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1002\/art.38814","article-title":"Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea","volume":"66","author":"Jacobe","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024112122583784000_47.8.1242.3","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.38853","article-title":"Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort","volume":"66","author":"Condie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024112122583784000_47.8.1242.4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"2024112122583784000_47.8.1242.5","first-page":"73","article-title":"The epidemiology of morphea (localized scleroderma) in Olmstead County 1960\u20131993","volume":"24","author":"Peterson","year":"1997","journal-title":"J Rheumatol"},{"key":"2024112122583784000_47.8.1242.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10600.x"},{"key":"2024112122583784000_47.8.1242.7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/bjd.12606","article-title":"Short- and long-term outcome of linear morphoea in children","volume":"169","author":"Piram","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024112122583784000_47.8.1242.8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.239"},{"key":"2024112122583784000_47.8.1242.9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance legacy registry","volume":"1","author":"Wu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2024112122583784000_47.8.1242.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090708"},{"key":"2024112122583784000_47.8.1242.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214697"},{"key":"2024112122583784000_47.8.1242.12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ddg.12724","article-title":"German guidelines for the diagnosis and therapy of localized scleroderma","volume":"14","author":"Kreuter","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024112122583784000_47.8.1242.13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-017-0269-x","article-title":"Morphea and eosinophilic fasciitis: an update","volume":"18","author":"Mertens","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2024112122583784000_47.8.1242.14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1365-2133.2008.09017.x","article-title":"Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study","volume":"160","author":"Kroft","year":"2009","journal-title":"Br J Dermatol"},{"key":"2024112122583784000_47.8.1242.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.30264"},{"key":"2024112122583784000_47.8.1242.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110210"},{"key":"2024112122583784000_47.8.1242.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07497.x"},{"key":"2024112122583784000_47.8.1242.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(00)90056-8"},{"key":"2024112122583784000_47.8.1242.19","first-page":"609","article-title":"Treatment of pediatric localized scleroderma with methotrexate","volume":"33","author":"Fitch","year":"2006","journal-title":"J Rheumatol"},{"key":"2024112122583784000_47.8.1242.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-008-0217-0"},{"key":"2024112122583784000_47.8.1242.21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2340\/00015555-2411","article-title":"Drug survival and predictors of drug survival for methotrexate treatment in a retrospective cohort of adult patients with localized scleroderma","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2024112122583784000_47.8.1242.22","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.7.847"},{"key":"2024112122583784000_47.8.1242.23","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2024112122583784000_47.8.1242.24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12969-019-0350-5","article-title":"Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study","volume":"17","author":"Li","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024112122583784000_47.8.1242.25","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000245727.40630.c3"},{"key":"2024112122583784000_47.8.1242.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066530"},{"key":"2024112122583784000_47.8.1242.27","unstructured":"U.S. Department of Health and Human Services . Common terminology criteria for adverse events version (CTCAE), version 4. [Internet. Accessed March 6, 2020.] Available from: evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"2024112122583784000_47.8.1242.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081284"},{"key":"2024112122583784000_47.8.1242.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep361"},{"key":"2024112122583784000_47.8.1242.30","first-page":"650","article-title":"Localized scleroderma severity index and global assessments: a pilot study of outcome instruments","volume":"35","author":"Arkachaisri","year":"2008","journal-title":"J Rheumatol"},{"key":"2024112122583784000_47.8.1242.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171381"},{"key":"2024112122583784000_47.8.1242.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.21264"},{"key":"2024112122583784000_47.8.1242.33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jdv.13790","article-title":"A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients","volume":"31","author":"Lis-Swiety","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112122583784000_47.8.1242.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371209"},{"key":"2024112122583784000_47.8.1242.35","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200108000-00006"},{"key":"2024112122583784000_47.8.1242.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.10095"},{"key":"2024112122583784000_47.8.1242.37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7525-2-55","article-title":"The PedsQL Family Impact Module: preliminary reliability and validity","volume":"2","author":"Varni","year":"2004","journal-title":"Health Quality Life Outcomes"},{"key":"2024112122583784000_47.8.1242.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"2024112122583784000_47.8.1242.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T07:23:16Z","timestamp":1732260196000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,1]]},"published-print":{"date-parts":[[2020,8,1]]}},"alternative-id":["10.3899\/jrheum.190311"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190311","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}